| 1 |
NCT02581501 |
Withdrawn |
Prospective Phase I Study of GAX for Metastatic Pancreatic Cancer |
|
- Drug: GAX - Gemcitabine, Abraxane and Xeloda
|
Interventional |
Phase 1 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Identification of Maximum Tolerated Dose and Dose Intensity in Patients with Pancreatic Cancer
- Progression Free Survival
|
0 |
All |
18 Years and older (Adult, Senior) |
NCT02581501 |
StamfordH |
|
February 2016 |
December 2016 |
December 2016 |
October 21, 2015 |
December 6, 2016 |
|
- Stamford Hospital Bennett Cancer Center
Stamford, Connecticut, United States
|
| 2 |
NCT02934984 |
Recruiting |
Circulating Cell-free Tumor DNA(ctDNA) in Pancreatic Cancer |
|
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Rates of recurrence in pancreatic cancer patients
- Rates of death in pancreatic cancer patients
|
100 |
All |
20 Years to 90 Years (Adult, Senior) |
NCT02934984 |
2016-07-054 |
|
July 2016 |
July 2019 |
January 2020 |
October 17, 2016 |
October 17, 2016 |
|
- Samsung Medical Center
Seoul, Korea, Republic of
|
| 3 |
NCT02555735 |
Recruiting |
Exceptional Responders With Pancreatic Cancer to Chemotherapy |
|
- Drug: Standard of care chemotherapy
|
Observational |
|
- Adera Labs, LLC
- Memorial Sloan Kettering Cancer Center
- University of Nebraska
- (and 3 more...)
|
Industry / Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Identify exceptional responders with pancreatic cancer to standard of care chemotherapy
- Correlation of genomic profiles from circulating tumor cells with overall survival
|
30 |
All |
18 Years and older (Adult, Senior) |
NCT02555735 |
ADRL-003 |
|
October 2015 |
September 2017 |
September 2018 |
September 22, 2015 |
October 20, 2015 |
|
- Oncology and Hematology Specialists
Denville, New Jersey, United States
|
| 4 |
NCT02449967 |
Withdrawn |
HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Pancreatic Cancer |
|
- Procedure: interventional therapy
|
Interventional |
Phase 1
Phase 2 |
- Fuda Cancer Hospital, Guangzhou
- Fuda Cancer Hospital, Guangzhou
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of participants with Adverse events
- Percentage of lesions that show no sign of recurrence 12 months after interventional therapy
- Progress free disease (PFS)
- Overall survival (OS)
|
0 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT02449967 |
Pancreatic Cancer HepaSphere |
|
May 2015 |
June 2018 |
June 2020 |
May 21, 2015 |
August 5, 2015 |
|
- Central laboratory in Fuda cancer hospital
Guangzhou, Guangdong, China
|
| 5 |
NCT00897832 |
Completed |
Biomarkers in Predicting Response to Treatment in Patients Who Have Undergone Surgery for Pancreatic Cancer |
|
- Other: laboratory biomarker analysis
|
Observational |
|
- Vanderbilt-Ingram Cancer Center
- National Cancer Institute (NCI)
- Vanderbilt-Ingram Cancer Center
|
Other / NIH |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Determination if a method of extracting and identifying biomarkers from tissues of the quantity obtained from typical biopsy can be applied in the setting of pancreatic cancer
|
50 |
All |
Child, Adult, Senior |
NCT00897832 |
VICC GI 0666
P30CA068485
VU-VICC-GI-0666
VU-VICC-061225 |
|
January 2007 |
December 2007 |
December 2007 |
May 12, 2009 |
March 5, 2013 |
|
- Vanderbilt-Ingram Cancer Center - Cool Springs
Nashville, Tennessee, United States - Vanderbilt-Ingram Cancer Center at Franklin
Nashville, Tennessee, United States - Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States
|
| 6 |
NCT00900003 |
Completed |
Studying Biomarkers in Patients With Pancreatic Cancer |
|
- Genetic: protein analysis
- Other: laboratory biomarker analysis
|
Observational |
|
- Vanderbilt-Ingram Cancer Center
- National Cancer Institute (NCI)
- Vanderbilt-Ingram Cancer Center
|
Other / NIH |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Cellular localization of BRCA1 as a predictor of response to cytotoxic agents or radiotherapy
- Correlation of pre-treatment markers with survival and recurrence
- Application of a method of extracting and identifying secreted cytokines and growth factors from biopsy tissue to the pancreatic cancer population
|
53 |
All |
Child, Adult, Senior |
NCT00900003 |
VICC GI 0717
P30CA068485
VU-VICC-GI-0717
VU-VICC-070366 |
|
May 2007 |
March 2013 |
March 2013 |
May 12, 2009 |
December 12, 2013 |
|
- Vanderbilt-Ingram Cancer Center - Cool Springs
Nashville, Tennessee, United States - Vanderbilt-Ingram Cancer Center at Franklin
Nashville, Tennessee, United States - Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States
|
| 7 |
NCT02451982 |
Recruiting |
Neoadjuvant/Adjuvant GVAX Pancreas Vaccine (With CY) With or Without Nivolumab Trial for Surgically Resectable Pancreatic Cancer |
|
- Drug: Cyclophosphamide
- Biological: GVAX pancreatic cancer
- Drug: Nivolumab
|
Interventional |
Phase 1
Phase 2 |
- Sidney Kimmel Comprehensive Cancer Center
- Sidney Kimmel Comprehensive Cancer Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Median IL17A expression in vaccine-induced lymphoid aggregates found in surgically resected pancreatic tumors
- Number of participants experiencing immune-related toxicities (IRAEs)
- Overall Survival
- Disease Free Survival
|
50 |
All |
18 Years to 100 Years (Adult, Senior) |
NCT02451982 |
J1568
IRB00050517 |
|
February 2016 |
June 2019 |
February 2020 |
May 22, 2015 |
March 14, 2018 |
|
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, United States
|
| 8 |
NCT00836407 |
Completed
Has Results |
Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer |
|
- Drug: Ipilimumab
- Biological: Pancreatic Cancer Vaccine
|
Interventional |
Phase 1 |
- Sidney Kimmel Comprehensive Cancer Center
- Sidney Kimmel Comprehensive Cancer Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Determine if Ipilimumab Alone or in Combination With Pancreatic Tumor Vaccine Has an Acceptable Safety Profile (Less Than 33% Unacceptable Toxicity) in Subjects With Locally Advanced, Unresectable or Metastatic Pancreatic Adenocarcinoma
- Overall Survival (OS)
- To Estimate Overall Response Rate (ORR), Immune Related Best Overall Response Rate (irBOR), Progression Free Survival (PFS), and Duration of Response in Patients Receiving Treatment.
- (and 2 more...)
|
30 |
All |
18 Years and older (Adult, Senior) |
NCT00836407 |
J0834
BMS # CA184-081 |
|
February 2009 |
July 2012 |
July 2012 |
February 4, 2009 |
December 10, 2013 |
December 10, 2013 |
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, United States
|
| 9 |
NCT03460769 |
Recruiting |
Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT) |
- Pancreatic Cancer
- Chronic Pancreatitis
- Diabetes Mellitus Type 3c
|
- Other: Data Management and Monitoring
|
Observational |
|
- M.D. Anderson Cancer Center
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- M.D. Anderson Cancer Center
|
Other / NIH |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Protocol and Regulatory Compliance Monitoring of Regulatory Documents for Consortium Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC)
|
452 |
All |
40 Years to 84 Years (Adult, Senior) |
NCT03460769 |
PA17-0674
1U01DK108328-01 |
|
November 1, 2017 |
November 2020 |
November 2020 |
March 9, 2018 |
March 9, 2018 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
| 10 |
NCT03398291 |
Not yet recruiting |
Simultaneous Resection of Pancreatic Cancer and Liver Oligometastasis After Induction Chemotherapy |
- Pancreatic Cancer
- Liver Metastases
- Surgery
|
- Procedure: Synchronous resection of primary pancreatic cancer and liver oligometastasis
- Drug: Standard chemotherapy
|
Interventional |
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Real overall survival
- Overall survival
- Quality of life
- (and 2 more...)
|
300 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT03398291 |
CSPAC-1 |
|
June 1, 2018 |
June 1, 2023 |
June 1, 2025 |
January 12, 2018 |
January 16, 2018 |
|
- Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University
Shanghai, Shanghai, China
|
| 11 |
NCT02162823 |
Completed |
Clinical Trial of Pancreatic Cancer in Stockholm. |
|
- Procedure: Pancreatic Surgery
|
Observational |
|
- Karolinska University Hospital
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Survival
- Factors influencing survival
|
600 |
All |
18 Years to 85 Years (Adult, Senior) |
NCT02162823 |
2006/1089-31/4 |
SPP |
May 2007 |
February 2017 |
February 2017 |
June 13, 2014 |
August 31, 2017 |
|
- Karolinska University Hospital, Gastrocentrum
Stockholm, Sweden
|
| 12 |
NCT03250078 |
Recruiting |
A Pancreatic Cancer Screening Study in High Risk Individuals Including Those With New-Onset Diabetes Mellitus |
|
- Diagnostic Test: MRI/MRCP
|
Observational |
|
- Western Connecticut Health Network
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Early Stage Pancreatic Cancer or Precursor Lesions
- Serial Pancreatic MRI Screening
- Serum Bio-bank
|
800 |
All |
50 Years to 80 Years (Adult, Senior) |
NCT03250078 |
NH 16-17 |
|
November 2016 |
November 2021 |
November 2023 |
August 15, 2017 |
August 15, 2017 |
|
- Danbury Hospital
Danbury, Connecticut, United States - New Milford Hospital
New Milford, Connecticut, United States - Norwalk Hospital
Norwalk, Connecticut, United States
|
| 13 |
NCT02079623 |
Unknown † |
Electroporation (NanoKnife) as Treatment for Advanced Pancreatic Cancer |
|
- Procedure: Electroporation/ Nano knife treatment
- Device: NanoKnife
|
Interventional |
Phase 3 |
- Aalborg Universitetshospital
- Uppsala University Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Tumor response
- CA-19-9
- Overall survival
|
25 |
All |
18 Years and older (Adult, Senior) |
NCT02079623 |
PCaNanoK |
NanoKnife |
November 2013 |
November 2015 |
November 2015 |
March 6, 2014 |
March 6, 2014 |
|
- Surgical Department of Gastroenterology, Aalborg University Hospital
Aalborg, Nothern Jutland, Denmark
|
| 14 |
NCT00614601 |
Terminated |
Low Dose Vaccine Study for Surgically Resected Pancreatic Cancer |
|
- Biological: HyperAcute(R)-Pancreatic Cancer Vaccine
|
Interventional |
Phase 2 |
- NewLink Genetics Corporation
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The primary objective of this Phase II trial is to assess disease-free survival (DFS) at one (1) year following initiation of treatment as the primary endpoint of the study in subjects treated with the HyperAcute®-Pancreatic Cancer Vaccine
- We will use overall survival and adverse events rates as secondary endpoints.
|
9 |
All |
18 Years and older (Adult, Senior) |
NCT00614601 |
NLG0305
OBA#0704-844 |
|
January 2008 |
May 2010 |
December 2014 |
February 13, 2008 |
June 26, 2015 |
|
- University of Louisville
Louisville, Kentucky, United States
|
| 15 |
NCT00994721 |
Completed |
A Phase III Study of Pancreatic Cancer |
|
|
Observational |
|
- National Health Research Institutes, Taiwan
- National Taiwan University Hospital
- Chang Gung Memorial Hospital
- (and 6 more...)
|
Other |
- Observational Model: Case Control
- Time Perspective: Prospective
|
- The primary end-point is recurrence-free survival.
- The secondary end-points are overall survival; local and distant control rate, and the quality of life.
|
147 |
All |
20 Years to 75 Years (Adult, Senior) |
NCT00994721 |
T3207 |
|
February 2009 |
January 2016 |
January 2016 |
October 14, 2009 |
May 4, 2016 |
|
- Chang-Gung Memorial Hospital
Taipei, Taiwan - Mackay Memorial Hospital
Taipei, Taiwan - National Taiwan University Hospital
Taipei, Taiwan
|
| 16 |
NCT00569387 |
Completed |
Vaccine Study for Surgically Resected Pancreatic Cancer |
|
- Biological: HyperAcute(R)-Pancreatic Cancer Vaccine
|
Interventional |
Phase 2 |
- NewLink Genetics Corporation
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The primary objective of this Phase II trial is to assess disease-free survival (DFS) at one (1) year following initiation of treatment as the primary endpoint of the study in subjects treated with the HyperAcute®-Pancreatic Cancer Vaccine
- We will use overall survival and adverse events rates as secondary endpoints.
|
73 |
All |
18 Years and older (Adult, Senior) |
NCT00569387 |
NLG0205
OBA#0701-829 |
|
December 2007 |
March 2011 |
December 2014 |
December 7, 2007 |
June 26, 2015 |
|
- Mayo Clinic - Scottsdale
Scottsdale, Arizona, United States - University of Southern California
Los Angeles, California, United States - University of California - Irvine
Orange, California, United States - (and 15 more...)
|
| 17 |
NCT02677038 |
Recruiting |
Olaparib for BRCAness Phenotype in Pancreatic Cancer |
|
|
Interventional |
Phase 2 |
- M.D. Anderson Cancer Center
- AstraZeneca
- M.D. Anderson Cancer Center
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective Tumor Response Rate of Olaparib in Participants with Pancreatic Cancer
- Efficacy of Olaparib in Participants with Pancreatic Cancer
|
24 |
All |
18 Years and older (Adult, Senior) |
NCT02677038 |
2015-0503
NCI-2016-00351 |
|
November 11, 2016 |
November 2019 |
November 2020 |
February 9, 2016 |
February 28, 2018 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
| 18 |
NCT02718859 |
Unknown † |
Combination of Irreversible Electroporation and NK Immunotherapy for Advanced Pancreatic Cancer |
|
- Biological: NK cells
- Procedure: irreversible electroporation (IRE )
|
Interventional |
Phase 1
Phase 2 |
- Fuda Cancer Hospital, Guangzhou
- Shenzhen Hank Bioengineering Institute
- Fuda Cancer Hospital, Guangzhou
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Relief degree
- Progress free survival（PFS）
- Overall survival（OS）
|
60 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT02718859 |
NK-pancre |
|
March 2016 |
March 2017 |
March 2017 |
March 24, 2016 |
July 19, 2016 |
|
- Central laboratory in Fuda cancer hospital
Guangzhou, Guangdong, China
|
| 19 |
NCT02080221 |
Recruiting |
BrUOG 292: FOLFOX-A For Metastatic Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial |
- Metastatic Pancreatic Cancer
|
|
Interventional |
Phase 2 |
- howard safran
- Brown University
- Lifespan
- (and 2 more...)
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Survival for patients with metastatic pancreatic cancer with first-line treatment with FOLFOX-A as compared to historical controls of gemcitabine alone.
- Toxicities associated with FOLFOX-A for metastatic pancreatic cancer
|
50 |
All |
18 Years and older (Adult, Senior) |
NCT02080221 |
BrUOG 292 |
|
August 2014 |
September 2018 |
December 2018 |
March 6, 2014 |
December 13, 2017 |
|
- Southcoast centers for cancer care
Fairhaven, Massachusetts, United States - Memorial Hospital of Rhode Island
Pawtucket, Rhode Island, United States - Lifespan Hospitals (The Miriam and RI Hospital, East Greenwich, Newport)
Providence, Rhode Island, United States
|
| 20 |
NCT03001505 |
Withdrawn |
Registry for Pancreatic Cancer |
|
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Other
|
- Overall survival
- Disease-free survival
- Metastasis
- Local recurrence
|
0 |
All |
18 Years and older (Adult, Senior) |
NCT03001505 |
Pro00075769 |
|
May 4, 2017 |
April 2037 |
April 2037 |
December 23, 2016 |
December 6, 2017 |
|
- Duke University Health System
Durham, North Carolina, United States - Duke University Medical Center
Durham, North Carolina, United States
|
| 21 |
NCT00885248 |
Unknown † |
Integrated Positron Emission Tomography - Computed Tomography (PET-CT) in Patients With Pancreatic Cancer |
|
|
Observational |
|
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Staging of pancreatic cancer
- Diagnosis of pancreatic cancer
|
70 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT00885248 |
2008-0623 |
|
January 2009 |
November 2009 |
December 2009 |
April 21, 2009 |
April 21, 2009 |
|
- Asan Medical Center
Seoul, Korea, Republic of
|
| 22 |
NCT02449135 |
Completed |
Nano Drug Interventional Therapy Using Digital Subtraction Angiography（DSA） for Pancreatic Carcinoma |
|
- Procedure: interventional therapy
|
Interventional |
Phase 1
Phase 2 |
- Fuda Cancer Hospital, Guangzhou
- Fuda Cancer Hospital, Guangzhou
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of participants with Adverse events
- Percentage of lesions that show no sign of recurrence 12 months after interventional therapy
- Progress free disease (PFS)
- Overall survival (OS)
|
60 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT02449135 |
Nano drug pancreatic cancer |
|
May 2015 |
February 2016 |
February 2016 |
May 20, 2015 |
February 25, 2016 |
|
- Central laboratory in Fuda cancer hospital
Guangzhou, Guangdong, China
|
| 23 |
NCT03417921 |
Not yet recruiting |
A Study of ABTL0812 in Pancreatic Cancer |
|
- Drug: sodium 2-hydroxylinoleic
|
Interventional |
Phase 1
Phase 2 |
- Ability Pharmaceuticals SL
- The Cleveland Clinic
|
Industry / Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
46 |
All |
18 Years and older (Adult, Senior) |
NCT03417921 |
ABT-C6-2017 |
Pancreatic |
September 1, 2018 |
September 1, 2020 |
September 2, 2020 |
January 31, 2018 |
January 31, 2018 |
|
|
| 24 |
NCT02459652 |
Active, not recruiting |
Neoadjuvant S-1 and Concurrent Radiotherapy for Borderline Resectable Pancreatic Cancer |
|
- Drug: S-1
- Radiation: Radiation Therapy
|
Interventional |
Phase 2 |
- Japan Adjuvant Study Group of Pancreatic Cancer
- Japan Agency for Medical Research and Development
- Pharma Valley Center
- Japan Adjuvant Study Group of Pancreatic Cancer
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- R0 resection rate
- Overall survival
- Disease-free survival
- (and 6 more...)
|
50 |
All |
20 Years to 75 Years (Adult, Senior) |
NCT02459652 |
JASPAC 05 |
|
September 2012 |
April 2016 |
September 2018 |
June 2, 2015 |
June 29, 2016 |
|
- Aichi Cancer Center
Nagoya, Aichi, Japan - Nagoya University Hospital
Nagoya, Aichi, Japan - Hirosaki University Hospital
Hirosaki, Aomori, Japan - (and 19 more...)
|
| 25 |
NCT02702986 |
Recruiting |
Safety and Feasibility of imILT Locally Advanced Pancreatic Cancer (LAPC) |
|
- Procedure: immunostimulating Interstitial Laser Thermotherapy
- Device: Laser
|
Interventional |
Phase 1 |
- Universita di Verona
- Clinical Laserthermia Systems AB
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
- The immunostimulating effects of imILT
- Quality of Life after the application of imILT on pancreatic cancer, using European Organisation for Research and Treatment of Cancer Quality of life Questionnaire C30
- (and 3 more...)
|
10 |
All |
18 Years to 85 Years (Adult, Senior) |
NCT02702986 |
CTP-2015-001 |
|
February 2016 |
March 2018 |
March 2018 |
March 9, 2016 |
August 24, 2016 |
|
- University of Verona Hospital
Verona, Italy
|
| 26 |
NCT02637596 |
Completed |
Quality of Life After Radiofrequency Ablation of Pancreatic Cancer |
|
- Procedure: Radiofrequency ablation
|
Interventional |
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Quality of life after RFA of pancreatic cancer
- 3- months perioperative morbidity and mortality
|
1 |
All |
18 Years and older (Adult, Senior) |
NCT02637596 |
NT 14579-3 |
|
February 2013 |
January 2014 |
December 2015 |
December 22, 2015 |
December 28, 2015 |
|
- Department of surgery Masaryk University Hostpital Brno
Brno, Bohunice, Czech Republic
|
| 27 |
NCT02343835 |
Recruiting |
Anti-Tumor Immunity Induced by IRE of Unresectable Pancreatic Cancer |
|
- Device: NanoKnife LEDC System
|
Interventional |
Phase 2 |
- Fuda Cancer Hospital, Guangzhou
- Fuda Cancer Hospital, Guangzhou
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Characterization of the intra-tumoral and systemic immune response to IRE in unresectable pancreatic cancers
- Comparison immune response between non-ablated and ablated pancreatic cancer and pre-ablated and post ablated serum
|
20 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT02343835 |
JF-20150113(4) |
|
January 2015 |
January 2017 |
January 2020 |
January 22, 2015 |
March 29, 2016 |
|
- FUDA Cancer Hospital
Guangzhou, Guangdong, China
|
| 28 |
NCT03392571 |
Not yet recruiting |
Phase II Study of NGC-Triple Regimen in Potentially Resectable Pancreatic Cancer Patients |
- Resectable Pancreatic Cancer
|
|
Interventional |
Phase 2 |
- Pancreatic Cancer Research Team
- Celgene Inc
- Pancreatic Cancer Research Team
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To evaluate 2 year survival from date of entry into study
- Determine the number and type of treatment-related adverse events as assessed by CTCAE 4.0
- Histological Response to Pre-Operative Therapy
- (and 5 more...)
|
70 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT03392571 |
PCRT 17-001 |
|
February 15, 2018 |
December 30, 2020 |
December 30, 2020 |
January 8, 2018 |
January 8, 2018 |
|
|
| 29 |
NCT01744353 |
Completed
Has Results |
BrUOG 278: FOLFOX-A For Pancreatic Cancer A Brown University Oncology Research Group Study |
- Metastatic Pancreatic Cancer
|
- Drug: Dose level 1
- Drug: Dose level 2/MTD
- Drug: Dose level 3
|
Interventional |
Phase 1 |
- Brown University
- Lifespan
- Rhode Island Hospital
- Memorial Hospital of Rhode Island
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Assessment of Toxicities to Define MTD of FOLFOX-Abraxane (A) for Newly Diagnosed, Advanced Pancreatic Cancer.
- Response Rate (if Patient's Tumor(s)Are Progressing or Being Controlled) Following Treatment With FOLFOX-A for Patients With Newly Diagnosed, Advanced Pancreatic Cancer.
|
35 |
All |
18 Years and older (Adult, Senior) |
NCT01744353 |
BrUOG 278 |
278 |
November 2012 |
September 2014 |
August 2015 |
December 6, 2012 |
April 11, 2016 |
April 11, 2016 |
- Memorial Hospital
Pawtucket, Rhode Island, United States - Rhode Island Hospital (including Newport and East Greenwich locations)
Providence, Rhode Island, United States - The Miriam Hospital
Providence, Rhode Island, United States
|
| 30 |
NCT01102569 |
Unknown † |
Pancreatic Cancer Genetics |
|
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Frequency of Three BRCA1/2 Mutations in Ashkenazi Jewish Patients
- Individual Frequency of Three Mutations
- Frequency of disease modifying mutations
|
100 |
All |
18 Years to 85 Years (Adult, Senior) |
NCT01102569 |
AAAC6344 |
|
January 2008 |
August 2015 |
August 2016 |
April 13, 2010 |
July 3, 2015 |
|
- Columbia University Medical Center
New York, New York, United States
|
| 31 |
NCT01995240 |
Completed |
Functional Magnetic Resonance Imaging of Pancreatic Cancer: a Feasibility and Reproducibility Study |
|
|
Interventional |
Not Applicable |
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Reproducibility of DCE, T2* and DWI MRI in pancreatic cancer.
- Compare in vivo measurements of tumor vascularity, hypoxia and stroma using DCE-MRI, T2* MRI and DWI with immunohistochemically determined markers of vascularity, hypoxia and stroma in pancreatic tumor tissue
- To explore the relation between in vivo measurements of tumor vascularity, hypoxia and stroma using DCE-MRI, T2* MRI and DWI and treatment outcome.
|
23 |
All |
18 Years and older (Adult, Senior) |
NCT01995240 |
NL40501.018.12 |
REMP |
April 2013 |
February 2017 |
February 2017 |
November 26, 2013 |
March 20, 2017 |
|
- Academic Medical Center
Amsterdam, Netherlands
|
| 32 |
NCT02358161 |
Unknown † |
Phase I/II Study of LDE225 With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer |
|
- Drug: gemcitabine and nab paclitaxel
|
Interventional |
Phase 1
Phase 2 |
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Novartis
- Celgene Corporation
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Dose limiting Toxicity (DLT) and MTD of LDE225 co-administered with gemcitabine and nab-paclitaxel
- Median survival
- Progression free survival
|
56 |
All |
18 Years and older (Adult, Senior) |
NCT02358161 |
AMCMEDONC 2013-215
2013-002370-51 |
MATRIX |
September 2013 |
September 2015 |
September 2015 |
February 6, 2015 |
February 6, 2015 |
|
- Academic Medical Center
Amsterdam, Netherlands
|
| 33 |
NCT02578732 |
Recruiting |
FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial |
- Locally Advanced Pancreatic Cancer
- Pancreatic Cancer
|
|
Interventional |
Phase 2 |
- howard safran
- Brown University
- Rhode Island Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response rate of FOLFOX-A for patients with locally advanced pancreatic cancer.
- Overall survival for patients with locally advanced pancreatic cancer treated with FOLFOX-A
|
60 |
All |
18 Years and older (Adult, Senior) |
NCT02578732 |
BrUOG 318 |
|
June 2016 |
January 2020 |
July 2020 |
October 19, 2015 |
February 5, 2018 |
|
- Rhode Island Hospital and The Miriam Hospital
Providence, Rhode Island, United States
|
| 34 |
NCT02148549 |
Unknown † |
Neoadjuvant FIRINOX for Borderline Resectable Pancreatic Cancer - a Pilot Study |
|
|
Interventional |
Phase 1 |
- Wakayama Medical University
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of participants with toxicity of FIRINOX therapy as neoadjuvant chemotherapy for borderline resectable pancreatic cancer.
- The resection rate of FIRINOX therapy as neoadjuvant chemotherapy for borderline resectable pancreatic cancer.
- The R0 resection rate of FIRINOX therapy as neoadjuvant chemotherapy for borderline resectable pancreatic cancer.
- The optimal treatment schedule of FIRINOX therapy as neoadjuvant chemotherapy for borderline resectable pancreatic cancer.
|
10 |
All |
20 Years to 74 Years (Adult, Senior) |
NCT02148549 |
FIRINOX
UMIN000013809 |
FIRINOX |
April 2014 |
February 2017 |
February 2017 |
May 28, 2014 |
July 23, 2015 |
|
- Nagoya University
Nagoya, Aichi, Japan - Kobe University
Kobe, Hyogo, Japan - Nara Prefectual Medical University
Kashihara, Nara, Japan - (and 6 more...)
|
| 35 |
NCT02050178 |
Completed |
Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer |
- Pancreatic Cancer
- Stage IV Pancreatic Cancer
|
- Drug: OMP-54F28, Nab-Paclitaxel and Gemcitabine
|
Interventional |
Phase 1 |
- OncoMed Pharmaceuticals, Inc.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety and tolerability of OMP-54F28 in combination with nab-paclitaxel and gemcitabine in patients with previously untreated Stage IV pancreatic cancer
- Pharmacokinetics (PK) of OMP-54F28 when administered in combination with nabpaclitaxel and gemcitabine to patients with previously untreated Stage IV pancreatic cancer
|
26 |
All |
18 Years to 90 Years (Adult, Senior) |
NCT02050178 |
54F28-002 |
|
November 2013 |
June 15, 2017 |
June 15, 2017 |
January 30, 2014 |
April 9, 2018 |
|
- USC/Norris Comprehensive Cancer Center
Los Angeles, California, United States - University of Colorado Hospital Anschutz Cancer Pavilion
Aurora, Colorado, United States - Indiana University Simon Cancer Center
Indianapolis, Indiana, United States - (and 2 more...)
|
| 36 |
NCT01692873 |
Recruiting |
Prognostic and Predictive Biomarkers of Therapeutic Response in Pancreatic Tumors |
|
- Procedure: suspected pancreatic tumor
|
Interventional |
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
|
300 |
All |
18 Years and older (Adult, Senior) |
NCT01692873 |
PACAomics / IPC 2011-004 |
PACAomics |
February 2012 |
December 2017 |
December 2017 |
September 25, 2012 |
June 21, 2017 |
|
- Marine GILABERT, MD
Marseille, France
|
| 37 |
NCT02005315 |
Completed |
A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer |
- Pancreatic Cancer
- Stage IV Pancreatic Cancer
|
- Drug: Vantictumab
- Drug: Nab-Paclitaxel
- Drug: Gemcitabine
|
Interventional |
Phase 1 |
- OncoMed Pharmaceuticals, Inc.
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Phase 1b: Safety and tolerability of vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated Stage IV pancreatic cancer
- Pharmacokinetics (PK) of vantictumab when administered in combination with nab-paclitaxel and gemcitabine to patients with previously untreated Stage IV pancreatic cancer
|
30 |
All |
18 Years to 90 Years (Adult, Senior) |
NCT02005315 |
18R5-003 |
|
September 2013 |
October 2017 |
November 2017 |
December 9, 2013 |
January 24, 2018 |
|
- USC/Norris Comprehensive Cancer Center
Los Angeles, California, United States - University of Colorado Hospital Anschutz Cancer Pavillion
Aurora, Colorado, United States - Indiana University Simon Cancer Center
Indianapolis, Indiana, United States - (and 2 more...)
|
| 38 |
NCT01542177 |
Recruiting |
A Study Using 18F-FAZA and PET Scans to Study Hypoxia in Pancreatic Cancer |
|
|
Observational |
|
- University Health Network, Toronto
- Canadian Cancer Society Research Institute (CCSRI)
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Measure the hypoxia level in Patients with Pancreatic Cancer using Positron Emission Tomography (PET) with 18F-Fluoroazomycin Arabinoside (18F-FAZA).
- Correlate FAZA PET uptake in pancreatic cancer with the extension of the disease.
- Correlate FAZA PET uptake in pancreatic cancer with CA 19-9 levels.
- (and 4 more...)
|
30 |
All |
18 Years and older (Adult, Senior) |
NCT01542177 |
FAZA-Pancreas |
|
February 2012 |
July 2019 |
July 2019 |
March 2, 2012 |
February 7, 2018 |
|
- Princess Margaret Hospital
Toronto, Ontario, Canada
|
| 39 |
NCT02506803 |
Recruiting |
Phase I Study of Neoadjuvant Chemotherapy for Patients With Borderline Resectable Pancreatic Cancer. |
|
|
Interventional |
Phase 1 |
- Wakayama Medical University
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of participants with toxicity of NAC-GEMABR therapy as neoadjuvant chemotherapy for borderline resectable pancreatic cancer.
- The resection rate of NAC-GEMABR therapy as neoadjuvant chemothterapy for borderline resectable pancreatic cancer.
- The R0 resection rate of NAC-GEMABR therapy as neoadjuvant chemotherapy for borderline resectable pancreatic cancer.
|
10 |
All |
20 Years to 79 Years (Adult, Senior) |
NCT02506803 |
NAC-GEMABR |
|
July 2015 |
June 2017 |
June 2017 |
July 23, 2015 |
May 12, 2016 |
|
- Wakayama Medical University
Wakayama, Japan
|
| 40 |
NCT01994681 |
Unknown † |
Testing Spectrosense EVA System for Detection of Pancreatic Cancer by Analyzing Volatile Organic Compounds (VOCs) in Exhaled Air |
|
|
Observational |
|
- Rauscher, Gregory E., M.D. PA
- Spectrosense Ltd.
|
Other / Industry |
- Observational Model: Case Control
- Time Perspective: Cross-Sectional
|
- Obtaining a set or sets of VOC bio-markers that will provide the best discrimination between Pancreatic Cancer sick population and healthy population.
|
100 |
All |
18 Years and older (Adult, Senior) |
NCT01994681 |
00004108 |
|
October 2013 |
October 2014 |
|
November 26, 2013 |
December 5, 2013 |
|
- Hackensack University Medical Center
Hackensack, New Jersey, United States
|
| 41 |
NCT02550847 |
Unknown † |
Evaluation of Prognosis With Integrated MRI/PET in Patients With Pancreatic Cancer |
|
- Device: The imaging biomarkers determined by MR-PET
|
Observational |
|
- National Taiwan University Hospital
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- The tumor recurrence rate after operation at 6 months
- The overall survival after operation at 6 months
|
100 |
All |
20 Years to 90 Years (Adult, Senior) |
NCT02550847 |
201407052MINC |
|
August 2014 |
April 2016 |
August 2016 |
September 16, 2015 |
April 14, 2016 |
|
- National Taiwan University Hospital
Taipei, Taiwan
|
| 42 |
NCT00727441 |
Active, not recruiting |
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Stage I or Stage II Pancreatic Cancer That Can Be Removed by Surgery |
|
- Biological: GVAX pancreatic cancer vaccine
- Drug: cyclophosphamide
|
Interventional |
Not Applicable |
- Sidney Kimmel Comprehensive Cancer Center
- National Cancer Institute (NCI)
- Sidney Kimmel Comprehensive Cancer Center
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety, as measured by local and systemic toxicity according to NCI CTCAE v3.0
- Feasibility
- Immune response
- (and 2 more...)
|
87 |
All |
18 Years to 120 Years (Adult, Senior) |
NCT00727441 |
JHOC-J0810, CDR0000600355
P30CA006973
JHOC-J0810
JHOC_NA_00015858 |
|
July 2008 |
December 2017 |
March 2018 |
August 4, 2008 |
January 12, 2017 |
|
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, United States
|
| 43 |
NCT02318095 |
Recruiting |
Gemcitabine/Nab-Paclitaxel With HIGRT in Resectable Pancreatic Cancer |
- Resectable Pancreatic Cancers
|
- Drug: Gemcitabine/nab-Paclitaxel
- Radiation: Radiation therapy
- Other: Sugical resection
- Drug: Adjuvant chemotheapy
|
Interventional |
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Feasibility of neoadjuvant gemcitabine/nab-paclitaxel and HIGRT in patients with potentially resectable pancreatic cancer.
- Grade >/=2 acute toxicity
- Resection rate
- R0 resection rate
|
40 |
All |
18 Years and older (Adult, Senior) |
NCT02318095 |
Pro00058865 |
|
February 17, 2015 |
January 2019 |
January 2020 |
December 17, 2014 |
January 9, 2018 |
|
- Duke Cancer Center
Durham, North Carolina, United States
|
| 44 |
NCT01492907 |
Completed |
Pilot Study of Meat-Borne Carcinogens and Pancreatic Cancer |
|
- Radiation: MeIQx
- Procedure: Pancreatectomy
|
Interventional |
Phase 1 |
- University of Minnesota - Clinical and Translational Science Institute
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Pharmacokinetic Metabolite Profile of Radiolabeled MeIQx in Blood
- Pharmacokinetic Metabolite Profile of Radiolabeled MeIQx in Urine
- Quantify [14C]MeIQx-DNA adducts in human pancreas
- Quantify ambient adducts in the human pancreas
|
8 |
All |
18 Years and older (Adult, Senior) |
NCT01492907 |
2011NTLS016 |
|
January 2012 |
April 2013 |
April 2013 |
December 15, 2011 |
August 22, 2014 |
|
- Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota, United States
|
| 45 |
NCT01272791 |
Completed |
Trial of Gemcitabine With or Without Bavituximab in Patients With Previously Untreated Stage IV Pancreatic Cancer |
- Metastatic Pancreatic Cancer
|
- Biological: bavituximab
- Drug: Gemcitabine
|
Interventional |
Phase 2 |
- Peregrine Pharmaceuticals
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival of patients with stage IV pancreatic cancer treated with gemcitabine alone or gemcitabine with bavituximab.
- Progression-free survival of patients with stage IV pancreatic cancer treated with gemcitabine alone or gemcitabine with bavituximab.
- Determine overall response rate (ORR)
- (and 3 more...)
|
70 |
All |
18 Years and older (Adult, Senior) |
NCT01272791 |
PPHM 1002 |
|
January 2011 |
February 2013 |
March 2013 |
January 10, 2011 |
April 19, 2017 |
|
- Ironwood Cancer & Research Centers
Chandler, Arizona, United States - Moores UCSD Cancer Center
La Jolla, California, United States - Lynn Cancer Institute
Boca Raton, Florida, United States - (and 16 more...)
|
| 46 |
NCT02745847 |
Not yet recruiting |
Re-irradiation With Stereotactic Body Radiotherapy for Relapsed Pancreatic Cancer |
|
- Radiation: Re-irradiation with SBRT
|
Interventional |
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The median survival time will be determined.
- The acute toxicities following SBRT will be determined by RTOG/EORTC Late Radiation Morbidity Scoring Criteria.
- The late toxicities following SBRT will be determined by RTOG/EORTC Late Radiation Morbidity Scoring Criteria.
- (and 4 more...)
|
30 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT02745847 |
ChangH Hosp |
|
May 2016 |
January 2019 |
December 2019 |
April 20, 2016 |
April 20, 2016 |
|
|
| 47 |
NCT01989000 |
Recruiting |
The Role of the Tumor Microenvironment of Pancreatic Cancer to Predict Treatment Outcome |
|
- Drug: Gadobutrol
- Drug: [F-18]HX4
- Drug: Gemcitabine
- (and 2 more...)
|
Interventional |
Not Applicable |
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Erasmus Medical Center
- Dutch Cancer Society
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Predictive value of pretreatment DWI, DCE-MRI, T2*, and 18F-HX4-PET/CT on overall survival in patients with pancreatic cancer treated with surgery and adjuvant chemotherapy or with neoadjuvant radiochemotherapy, surgery and adjuvant chemotherapy.
- Predictive value of pretreatment DWI, DCE-MRI, T2*, and 18F-HX4-PET/CT on recurrence free survival in patients with pancreatic cancer treated with surgery and adjuvant chemotherapy or with neoadjuvant radiochemotherapy, surgery and adjuvant chemotherapy.
- Predictive value of pretreatment DWI, DCE-MRI, T2*, and 18F-HX4-PET/CT on pathological response in patients with pancreatic cancer treated with neoadjuvant radiochemotherapy
- (and 4 more...)
|
95 |
All |
18 Years and older (Adult, Senior) |
NCT01989000 |
NL45913.018.13 |
MIPA |
November 2013 |
September 2017 |
September 2017 |
November 20, 2013 |
July 27, 2016 |
|
- Academic Medical Center
Amsterdam, Noord Holland, Netherlands - Erasmus MC
Rotterdam, Zuid Holland, Netherlands
|
| 48 |
NCT03497819 |
Active, not recruiting
New |
Autologous CARTmeso/19 Against Pancreatic Cancer |
|
- Biological: CARTmeso CART19
|
Interventional |
Early Phase 1 |
- First Affiliated Hospital of Wenzhou Medical Univeristy
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The Percentage of Adverse Events (AEs) ≥ grade 3 assessed through MedDra and CTCAE v4.03 [Time frame: from infusion to 3 month afterward]
- Overall Response Rate defined as any improvement measured by imaging following RECIST 1.1 [Time Frame: Day 14 and 1 month after infusion]
|
10 |
All |
18 Years to 65 Years (Adult) |
NCT03497819 |
YXA-meso19 |
|
October 1, 2017 |
October 31, 2019 |
October 31, 2020 |
April 13, 2018 |
April 13, 2018 |
|
- First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China
|
| 49 |
NCT01488552 |
Completed |
Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer |
- Stage IV Pancreatic Cancer
|
- Drug: Gemcitabine
- Drug: nab-paclitaxel
- Drug: FOLFIRINOX
- (and 3 more...)
|
Interventional |
Phase 1
Phase 2 |
- Pancreatic Cancer Research Team
- Pancreatic Cancer Research Team
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Complete Response Rate
- One-Year Survival Endpoint
- Efficacy Endpoints using biomarkers
- Observing toxicity outcomes
|
60 |
All |
18 Years and older (Adult, Senior) |
NCT01488552 |
PCRT 11-002 |
|
November 2011 |
August 2015 |
August 2016 |
December 8, 2011 |
August 18, 2016 |
|
- TGen Clinical Research Services (TCRS)
Scottsdale, Arizona, United States - Disney Family Cancer Center
Burbank, California, United States - Virginia Piper Cancer Institute (VPCI)
Minneapolis, Minnesota, United States - (and 2 more...)
|
| 50 |
NCT02756468 |
Unknown † |
Procalcitonin Reveals Early Dehiscence in Pancreatic Surgery: the PREDIPS Study |
|
- Other: pts operated for pancreatic cancer
|
Observational |
|
- University of Roma La Sapienza
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Sensitivity of PCT and CRP for anastomotic leak (AL) after pancreatic surgery
- Specificity of PCT and CRP for anastomotic leak (AL) after pancreatic surgery
- PCT and CRP cuts-off in 3rd POD with a good NPV for AL
- PCT and CRP cuts-off in 5th POD with a good NPV for AL
|
100 |
All |
18 Years to 100 Years (Adult, Senior) |
NCT02756468 |
PREDIPS |
PREDIPS |
January 2015 |
June 2016 |
December 2016 |
April 29, 2016 |
April 29, 2016 |
|
- Sant'Andrea University Hospital
Rome, Italy
|
Create an RSS feed from your search for:
Download the search results for: